News Column

SeeThruEquity Issues Update Note on TapImmune Highlighting New Grant Funded Clinical Trial and Recent Capital Raise of $2 Million

August 19, 2014

Category: Baystreet Newswire

Company: SeeThruEquity

ID: 419305

Date: Tuesday, August 19, 2014


New York, NY / ACCESSWIRE / August 19, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV). “We are very pleased by the recent $2M raise as it will help TapImmune proceed as planned in advancing its development programs to Phase II in 4Q14E. Additionally, TapImmune announced a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. These events significantly bolster TapImmune’s balance sheet and we are therefore reiterating our price target of $6.97 per share,” stated Ajay Tandon, Chief Executive Officer of SeeThruEquity. Highlights of the note are as follows: - Direct placement strengthens balance sheet. On August 11, 2014, TapImmune announced that it had entered into a definitive agreement with an institutional investor for a registered direct placement of $2mn of common stock at a price of $1.06 per share. In addition, the company will issue warrants to the investor to purchase up to 1.9mn shares of common stock. The warrants have an exercise price of $1.17 per share and are exercisable for five years following issuance. The offering is expected to close on or about August 14, 2014. We had modeled in TapImmune raising $7mn in equity from 2Q14-4Q14E, and are pleased by this announcement. - Folate receptor study will provide insight into therapy. On August 7, 2014, TapImmune announced that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. The folate receptor alpha peptides being used in this study are the same ones that are being used in a current Phase I study in breast and ovarian cancer. TapImmune has the exclusive option to license the folate receptor alpha technology for all indications. - Dr. Keith Knutson’s appointment bolsters advisory board. On June 12, 2014, TapImmune announced that Dr. Keith Knutson, Ph.D., been appointed to chair the company’s scientific advisory board. Dr. Knutson is currently Director of the Cancer Vaccines and Immune Therapies Program at the Vaccine & Gene Therapy Institute of Florida, Port St. Lucie, FL.TapImmune has licensed cancer vaccine technologies originating from Dr. Knutson’s former laboratory at the Mayo Clinic, which are currently completing Phase I clinical trials in breast and ovarian cancer and the previously announced folate receptor clinical study will take place. The note is available here: TPIV Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms. Please review important disclosures on our website at About TapImmune Inc.TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at for details. About SeeThruEquity SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street. For more information visit Contact: Ajay Tandon SeeThruEquity (646) 495-0939 Source: SeeThruEquity

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: ACCESSWIRE (Canada)

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters